Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

QIAGEN and Pfizer to Develop Companion Lung Cancer Diagnostic

By Pharmaceutical Processing | August 16, 2011

 

QIAGEN has entered into a partnership with Pfizer Inc. for
the development of a companion molecular diagnostic test for use with an
investigational Pfizer compound in global clinical development for treatment of
non-small cell lung cancer (NSCLC). Financial terms of the agreement were not
disclosed.

Pfizer’s investigational compound, dacomitinib
(PF-00299804), is an oral inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine
kinases. The HER (human epidermal growth factor receptor) signaling pathway
plays a role in the complex process of cell growth and metastasis, making it a
target for anti-cancer drugs.

QIAGEN’s proposed companion diagnostic will be based on its
proprietary KRAS assay technology, which reliably detects mutations of the KRAS
gene that are frequently found in human cancers. Because EGFR inhibitors are
generally effective in patients without these KRAS mutations, the QIAGEN assay
can be useful in identifying patients most appropriate for EGFR-inhibitor
therapies. QIAGEN recently submitted the application for Premarket Approval
(PMA) for KRAS companion diagnostics to the FDA for use with two other, separate
drugs targeting metastatic colorectal cancers. The Pfizer drug companion
diagnostic test is being specifically developed for use in lung cancer tissue.
It uses the same core assay component as the therascreen KRAS RGQ kit for
colorectal cancers but varies in the workflow to allow for lung tissue-specific
sample technology in a fully automated workflow.

QIAGEN and Pfizer will engage in collaborative efforts to
develop the KRAS companion diagnostic for use with dacomitinib (PF-00299804).
The global partnership covers clinical trials and submissions for a PMA
application in the United States
and the CE mark in Europe, as well as
applicable regulatory approvals in other regions.

“We are pleased to collaborate with Pfizer seeking to
advance personalized healthcare with a new potential tool in the fight against
non-small cell lung cancer, a major killer around the world,” commented
Dr. Stephen Little, Vice President Personalized Healthcare at QIAGEN.
“This partnership unites QIAGEN’s capabilities in companion diagnostics
with Pfizer’s scientific excellence and global presence to develop an
innovative diagnostic-therapeutic combination with the potential to improve the
standard of care for NSCLC patients.”

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE